Poniard Pharmaceuticals Inc.

poniard pharmaceuticals inc. - All News and Analysis

• Poniard Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript

  Seeking Alpha - 2008-05-24

  Question-and-Answer Session Operator Operator instructions We'll take our first question from Brett Holley with Oppenheimer & Co. Michael Barrick – Oppenheimer & Co. Oh, hi. This is actually Michael Barrick [ph] on behalf of Brett. I just have a question about the colorectal cancer trial. Acknowledging...

  Tags: Poniard Pharmaceuticals Inc.

• Poniard Pharmaceuticals Inc Q4 2007 Earnings Call Transcript

  Seeking Alpha - 2008-03-17

  Question-and-Answer SessionOperator Operator instructions We'll go first to Katherine Xu of Credit Suisse. Katherine Xu - Credit Suisse Hi, good afternoon. Jerry McMahon Good afternoon. Katherine Xu - Credit Suisse Jerry, I'm just curious, during around JPMorgan in January you said, from what your estimates,...

  Tags: Poniard Pharmaceuticals Inc.

Additional Resources

• Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin

  - 2008-11-24

  SOUTH SAN FRANCISCO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced an agreement with Baxter Oncology GmbH for the commercial manufacture and supply of injectable picoplatin drug product. Poniard is developing picoplatin, its lead product candidate, as a potential new...

• Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin

  - 2008-11-06

  SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced top-line results from its Phase 1 clinical trial of an oral formulation of picoplatin in patients with solid tumors showing that picoplatin achieves linear and dose-dependent plasma exposure when...

• Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update

  - 2008-10-30

  - Conference Call Today at 5 p.m. Eastern Time - SOUTH SAN FRANCISCO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the third quarter ended September 30, 2008. ...

• Poniard Pharmaceuticals Announces Upcoming Conference Participation

  - 2008-10-28

  SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that Company executives will participate in six upcoming conferences over the coming weeks during which they will provide a corporate overview, including a discussion of the clinical development program...

• Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30

  - 2008-10-23

  SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it will hold a conference call to discuss the Company's third quarter results and provide a corporate update, including an update on the ongoing development activities for picoplatin,...

• Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer

  - 2008-10-22

  - Updated Preliminary Results Presented at 20th EORTC-NCI-AACR Symposium - SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced positive incremental data from its randomized, controlled Phase 2 clinical trial of picoplatin in patients...

• Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer

  - 2008-10-22

  - Updated Results Presented at 20th EORTC-NCI-AACR Symposium - SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced positive incremental data from its ongoing Phase 2 clinical trial of picoplatin in combination with docetaxel...

• Poniard Pharmaceuticals' Picoplatin Named by Windhover Among Top 10 Most Promising Oncology Products

  - 2008-10-21

  SOUTH SAN FRANCISCO, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that its lead product candidate, picoplatin, has been selected by an independent committee assembled by Windhover Information Inc. as one of the Top 10 most promising oncology projects in...

• Poniard Pharmaceuticals Exercises Option to Draw Down $10 Million Second Tranche of Loan Facility

  - 2008-10-06

  - Proceeds to Fund Company Operations into 2010 - SOUTH SAN FRANCISCO, Calif., Oct. 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. , a biopharmaceutical company focused on oncology, today announced that it has exercised its option to draw down a $10.0 million second tranche, which represents the balance...

• Market Review for Poniard Pharmaceuticals, Inc.

  - 2008-02-04

  M2 PRESSWIRE-4 February 2008-The SI Report: Market Review for Poniard Pharmaceuticals, Inc.C1994-2008 M2 COMMUNICATIONS LTD RDATE:04022008 Streetinvesting.com has now resumed our progressive review of Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), after it traded down less than 1% Monday, noon with...

• Poniard Pharmaceuticals Provides 2008 Clinical Goals for Picoplatin.

  - 2008-01-07

  M2 PRESSWIRE-7 January 2008-The Maybach Financial Group: Poniard Pharmaceuticals Provides 2008 Clinical Goals for PicoplatinC1994-2008 M2 COMMUNICATIONS LTD RDATE:07012008 Maybach Financial Group is a syndicate of financial analysts, with a core group representing over 250 years of total investing...

• Progressive Following on Poniard Pharmaceuticals Inc.

  - 2008-01-07

  M2 PRESSWIRE-7 January 2008-Streetinvesting.com: Progressive Following on Poniard Pharmaceuticals IncC1994-2008 M2 COMMUNICATIONS LTD RDATE:07012008 Stocks lost ground Friday following the government's much anticipated report on the country's employment outlook which stated a weaker-than-expected job growth and a definite...

• Poniard keeps on moving forward

  - 2007-12-17

  SOUTH SAN FRANCISCO, Calif. -- Poniard Pharmaceuticals Inc., a biopharmaceutical company focused on oncology, has provided an update of its picoplatin development program in small-cell lung cancer SCLC, colorectal cancer and hormone refractory prostate cancer. In a presentation at a recent health care conference chairman and chief executive...

• PONIARD PHARMACEUTICALS REPORTS 2ND QTR NET LOSS OF $8.5 MIL.(Financial report)

  - 2007-09-01

  Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, has reported on its corporate progress and financial results for the quarter ended June 30, 2007. "Poniard achieved significant milestones during the last quarter, including the initiation of our pivotal Phase 3...

• Lt. Governor John Garamendi to Tout Bio-Technology as Key to State's Economic Future During Wednesday Meetings at Prominent South San Francisco Bio Science Facilities

  - 2007-07-31

  SOUTH SAN FRANCISCO, Calif. -- Lieutenant Governor John Garamendi on Wednesday will announce that he will recommend the creation of a state advisory committee on biotechnology to help support and spur the growth of California's economy. Garamendi, as chair of the newly revitalized Commission for Economic Development, CED will recommend...

• Poniard Pharmaceuticals Inc. Under Current Review.

  - 2007-06-05

  M2 PRESSWIRE-5 June 2007-www.streetinvesting.com: Poniard Pharmaceuticals Inc. Under Current ReviewC1994-2007 M2 COMMUNICATIONS LTD RDATE:05062007 Please visit www.Streetinvesting.com for the full report. Both Wall Street and Bay Street climbed higher Friday as traders, enthused by data on job creation,...

• Poniard Pharmaceuticals Announces Public Offering of Common Stock Pricing.

  - 2007-04-25

  M2 PRESSWIRE-25 April 2007-Breaking News: Poniard Pharmaceuticals Announces Public Offering of Common Stock PricingC1994-2007 M2 COMMUNICATIONS LTD RDATE:25042007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the ...

• Shareholders alert for Poniard Pharmaceuticals, Inc.

  - 2007-04-25

  M2 PRESSWIRE-25 April 2007-Biotech News: Shareholders alert for Poniard Pharmaceuticals, IncC1994-2007 M2 COMMUNICATIONS LTD RDATE:25042007 Shareholders alert for Poniard Pharmaceuticals, Inc (NASDAQ:PARD) Poniard Pharmaceuticals, Inc., a biotechnology company, engages in the discovery, development, and commercialization of cancer therapy ...

• Incorporated: 1984
• CEO: Dr. Gerald McMahon
• Employees: 51